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Abstract
Background and purpose Moyamoya angiopathy (MMA) is a chronic progressive disorder, but imaging changes observed 
over time are not yet characterized in European populations. We analyzed the progression of MMA with magnetic resonance 
imaging and angiography (MRI and MRA) in our Finnish MMA registry. Stage classification based on MRA findings was 
used to evaluate the progress of the disease.
Methods 32 patients with MMA were evaluated with MRI and MRA and compared to previous imaging. The follow-up 
imaging was done 103 (range 6–380) months after the MMA diagnosis, and 64 (range 6–270) months after the previous 
imaging. We graded the disease stage according to the previously described MRA grading scale.
Results No acute lesions, including silent ischemic strokes were found in the follow-up image compared to latest available 
previous image. One patient had an asymptomatic intracerebral hemorrhage since the last imaging. Ivy sign was observed in 
22% of the patients in the follow-up image. Six percent (n = 2) had microhemorrhages and 9% (n = 3) white matter lesions in 
the follow-up imaging. The MRA grade was evaluated from the follow-up images and it was 3 and 2.5 points (right and left, 
respectively). Fifty-six percent (n = 18) had old ischemic lesions in the follow-up image. Majority (71%) of the old ischemic 
lesions were large anterior circulation infarcts.
Conclusions A slow progression of MMA-related changes on MRI/MRA was found, being in line with our previous reports 
suggesting a rather benign course of the disease in the Finnish population.
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Introduction
Moyamoya disease (MMD) and moyamoya syndrome 
(MMS), referred as the moyamoya angiopathy (MMA), 
is a chronic progressive steno-occlusive angiopathy at the 
distal portions of internal carotid arteries (ICAs) and their 
proximal branches, with typical collateral artery forma-
tion, the moyamoya vessels. Digital subtraction angiogra-
phy (DSA) is considered the golden standard for imaging 
the MMA, however, the non-invasive magnetic resonance 
imaging (MRI) is currently commonly used for diagnos-
tic and follow-up imaging [1]. The radiological findings 
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associated with MMD include stenosis or occlusion of the 
large branches of the internal carotid artery (middle cerebral 
artery, MCA, and anterior cerebral artery, ACA), rarely the 
posterior cerebral artery (PCA), development of collaterals 
in the basis of the brain giving the “puff of smoke” impres-
sion, ischemic and hemorrhagic parenchymal brain lesions, 
ivy sign, cerebral microbleeds (CMBs), and white matter 
lesions (WMLs). While in general, MMA changes are irre-
versible and progressive, the speed and extent of the progress 
of the MMA changes in brain parenchyma and arterial tree 
in European white patient populations are not well-studied. 
Most of the studies concerning these radiological findings 
are done in Asian populations [2–5], and there is one single 
study by Wenz concerning CMBs in the German popula-
tion [6]. We accomplished follow-up imaging with MRI 
and MRA in 32 Finnish MMA patients to evaluate silent/
asymptomatic progression of the angiopathy, the occurrence 
of ivy sign, CMBs and WMLs, silent or overt infarcts and 
intracerebral hemorrhages, and to grade the disease stage.
Materials and methods
This study was performed at the Departments of Neurol-
ogy and Neurosurgery, Helsinki University Hospital (HUH), 
Helsinki, Finland. The local ethics committee approved the 
study (154/13/03/00/10). All MMA patients who agreed to 
come for an outpatient clinical follow-up visit coupled with 
MRI/MRA gave a written consent and were included to this 
study.
We searched for all diagnosed MMD and MMS patients 
referred to our hospital, and collected patient data into a 
detailed database as reported earlier [7], and called them 
for a face-to-face follow-up visit including head MRI and 
head and cervical artery MRA. Our HUH-MMA database 
includes detailed data on the patients’ medical history, fam-
ily history of stroke and MMA, medication on admission 
and preventive medication at discharge, hospital admission 
data, clinical manifestation and time course, treatment and 
procedures, discharge details, laboratory tests on admission, 
and radiological data. Our HUH-MMA database includes 
patients from whole Finland, but for this study we limited 
the follow-up imaging to those living in HUH catchment 
area, with a population of 1.6 million.
MRI and MRA
In this study, all patients underwent MRI and MRA imag-
ing with a 3.0 T scanner (Philips Achieva, Best, the Neth-
erlands). The imaging sequences included T1-weighed 
and T2-weighed 3D-sequences with isotropic acquisition 
in sagittal plane, axial FLAIR sequence (slice thickness 
4 mm), axial diffusion-weighed sequence (slice thickness 
4 mm, spacing 5 mm), axial susceptibility-weighed sequence 
(thickness 1 mm, spacing 0.5 mm), time-of flight (TOF) 
MRA of the cerebral arteries, and flow-based MRA of the 
cervical arteries. For the patients with extracranial-intracra-
nial bypasses, the cerebral artery TOD MRA was performed 
also with gadolinium contrast agent (Dotarem 279.3 mg/ml, 
Guerbet, France). We used the MRA grading described by 
Houkin et al. to evaluate the progress of the disease [8]. 
Both hemispheres were evaluated separately. In the grading 
system ICA and MCA were graded from 0 to 3 (0 normal, 
3 invisible) and ACA and PCA from 0 to 2 (0 normal, 2 
invisible). The MRA score is the total points from four main 
cerebral arteries (minimum 0 and highest 10). The MRA 
score was classified into four grades (MRA score 0–1, grade 
1; 2–4, grade 2; 5–7 grade 3; and 8–10, grade 4) [8]. We 
also evaluated the presence of ivy sign, CMBs, pattern of 
ischemic lesions, and presence of WMLs, and occurrence of 
new silent or overt ischemic or hemorrhagic lesions since 
previous imaging. Patients with revascularization operation 
done were evaluated to see if the bypasses were still patent. 
The analysis of the radiological data was done by a neuro-
radiologist (JP) together with a neurologist (MS). Ischemic 
lesions were divided into small (< 1.5 cm) and large ante-
rior or posterior lesions. Extent of WMLs was classified 
according to the Fazekas classification [9]. The sequences 
of the latest previous image used in the comparison to see 
the progression varied because they were done in the normal 
clinical need settings and not systemically using the same 
sequences as done in the imaging performed for this study.
Statistical analyses
Frequencies, means, and medians were calculated using 
the SPSS software (IBM Corp. Released 2012. IBM SPSS 
Statistics for Windows, Version 23.0. Armonk, NY: IBM 
Corp.). Crosstabs and Chi-squared test were used to com-
pare the groups. A two-sided p value < 0.05 is considered 
significant.
Results
32 patients (7 male, 22%) agreed to follow-up imaging (two 
had MMS; one with Down’s syndrome with bilateral dis-
ease and one with neurofibromatosis type 1 with unilateral 
disease, see Table 1 for demographic data). Seventy-three 
percent (22/30) of the MMD patients had bilateral disease. 
Ten (31%) patients had had revascularization surgery. The 
follow-up imaging was done 103 (range 6–380) months after 
the initial diagnosis of MMV and 64 (range 6–270) months 
after previous (baseline) imaging.
Ivy sign was present in 7 (22%) patients and 2 of these 
had had revascularization operation done. Interestingly, in 
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two patients ivy sign was present in previous image but not 
in the follow-up image. The amount of ischemic strokes 
(p = 0.36), multiple ischemic strokes (p = 0.42), nor the loca-
tion of ischemic strokes (p = 0.67) did not differ between ivy 
sign-positive and ivy sign-negative patients. Only 2 (6%) 
patients had CMBs, one of them being asymptomatic and 
the other one having had ischemic stroke as the present-
ing pathology at the time of diagnosis. None had CMBs in 
the previous image, but only 11 had had SWI/T2* sequence 
done in the baseline image. 91% of the patients had no 
WML (Fazekas 0) and the rest (three patients) had only mild 
WML (Fazekas 1) and one of those had had revasculariza-
tion operation. Only one had WML in the previous imaging 
but again only 26 had had FLAIR-sequence and thus could 
be evaluated. Twelve (38%) patients had completely normal 
brain parenchyma in the follow-up image. In the Table 2 the 
imaging findings are summarized.
Five (16%) patients were asymptomatic at the time of 
diagnosis. One of those patients had CMBs, one had ivy 
sign, and none had WMLs in the follow-up image. All of 
these patients remained asymptomatic during the follow-up 
time. One, the only MMS patient with Down’s syndrome, 
had progression of stenosis in the arteries.
None had acute ischemic or hemorrhagic stroke in the 
follow-up image. None had new silent ischemic strokes 
compared to previous imaging. Fifty-six percent (n = 18) of 
patients had old ischemic lesions, 38% had cortical lesion, 
and 41% had subcortical lesions in the follow-up image. 
Most of the old ischemic lesions located in MCA (17%), bor-
der zone (28%), or both of previous (33%) territories. Forty-
four percent of the patients had multiple ischemic lesions in 
the follow-up image. Seventy-one percent of the ischemic 
lesions were large anterior circulation lesions, 6% were 
large posterior and the rest were small lesions in the follow-
up image. Fifty-three percent of the patients had bilateral 
lesions in the follow-up image. None of the 8 patients with 
unilateral MMD had progressed to bilateral MMD during 
the mean follow-up period of 71 (range 12–161) months.
Only one patient had a new vascular event in the follow-
up image since the last imaging. Initially this patient sought 
medical help because of tinnitus at the age of 39. The first 
brain MRI was normal, although the MRA disclosed a bilat-
eral MMD. In the follow-up MRI performed 9 years later 
there were signs of old subcortical parenchymal hemorrhage 
on the right. However, she had not experienced neurological 
symptoms.
Ten patients had had revascularization opera-
tions, 3 (1 bilateral, 2 unilateral) of them had had 
Table 1  Demographic data and disease type of Finnish MMV 
patients (n = 32)
EDAS encephalo-duro-arterio-synangiosis; MMD moyamoya disease; 
MMS moyamoya syndrome; ICH intracerebral hemorrhage; SAH sub-
arachnoid hemorrhage; STA-MCA superficial temporal artery to mid-
dle cerebral artery; TIA transient ischemic attack
a Down’s syndrome and neurofibromatosis 1 each
Patients
All patients n (%) 32 (100)
Female (%) 25 (78)
Male (%) 7 (22)
Age at the time of first symptoms, mean (range) 35 (4–62)
Age at the time of first symptoms, median 36
Age at the time of diagnosis, mean (range) 37 (5–67)
Age at the time of diagnosis, median 38.5
Age at the time of follow-up, mean (range) 43.8 (18–70)
Age at the time of follow-up, median 48
Type of disease
 MMD (%) 30 (94)
 MMD bilateral (%) 22 (69)
 MMSa (%) 2 (6)
Surgery (%) 10 (31)
 STA-MCA (unilateral n) 7 (2)
 EDAS (unilateral n) 3 (2)
Table 2  Imaging findings of the 
previous (baseline) image and 
last (follow-up) MR imaging
CMB cerebral microbleeds; MM moyamoya; MRA magnetic resonance angiography; MRI magnetic reso-
nance imaging; WML white matter lesions
Previous imaging Follow-up imaging
MRI
 Normal parenchyma 13 patients 12 patients
 New ischemic lesions 0
 Intracerebral hemorrhage 1 (silent)
 Silent (covert) infarction 1
 CMB (no of patients with SWI/T2* sequences) 0 (11/32) 2 (32/32)
 WMH (no of patients with T2/FLAIR sequences) 1 mild (26/32) 3 mild (32/32)
 Ivy sign (no of patients with FLAIR sequence) 3 (24/32) 7 (32/32)
MRA
 Unilateral MM 8 8
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encephalo-duro-arterio-synangiosis operation and the rest 
(5 bilateral, 2 unilateral) superficial temporal artery to mid-
dle cerebral artery (STA-MCA) bypass. We evaluated 10 
hemispheres of those who had had STA-MCA operation and 
only 1 of 10 of the bypasses was not patent.
Median MRA grade was 3 and 2.5 (right and left, respec-
tively), median scores were 6 and 4.5 points (right and left, 
respectively, mean 4.9 ± 2.5, 4.3 ± 2.7) in 28 patients with 
evaluable MRA data.
Discussion
Our results in 32 MMA patients with a mean follow-up of 
64 months between the two MRI/MRA imaging time points 
suggest a fairly slow progress of MMA in Finnish patients, 
adding new insights to our previous observations of a low 
frequency of clinical events in the same patient registry [10]. 
In line with few clinical events, new ischemic or hemor-
rhagic lesions were found in one patient only, and all the 
unilateral cases remained unilateral. Only one new vascular 
event was found, the sign of an old subcortical parenchymal 
hemorrhage. Ivy sign was observed in 22%, CMBs in 6%, 
and WMLs in 9% of the patients.
There is a lack of studies reporting regular clinical and 
imaging follow-up of MMA patients in the white popula-
tions, describing disease progress over long time. This leads 
to a serious shortcoming in understanding MMA disease 
dynamics. MMA per se may be multifactorial and heteroge-
neous group of different syndromes presenting with a unify-
ing vasculopathic appearance and thus the vascular changes 
may progress with different speeds in different patient sub-
groups, individuals, or ethnic groups depending on factors 
we are yet unaware of. Therefore, it is useful to screen a con-
secutive and large-enough patient population with follow-up 
imaging studies, along with clinical evaluations, for describ-
ing the disease progress speed (i.e. natural course of the 
disease) as well as to look into various subgroups whether 
disease progress differs in certain subpopulations. This may 
further help in identifying subgroups of patients that need 
close monitoring and perhaps more aggressive treatments 
and ignites further research interest deciphering underlying 
unique mechanisms. Currently, there are two guidelines for 
MMA, one Japanese and one French. The French guideline 
suggests that MRI and MRA imaging should be done on a 
case-by-case basis according to the clinical and radiologi-
cal evolution of the patient, but at least once a year during 
the first years [11]. Japanese guidelines do not deliver a 
clear follow-up approach [1]. However, the lack of broad 
data on the disease progression, and lack of evidence-based 
strategies to react to imaging-based vascular or parenchy-
mal changes, make it difficult to give long-term follow-up 
plan perspectives. Therefore, more reports on large MMV 
patient populations with clinical and imaging-based follow-
up data are necessary for developing guidelines for clinical 
use. According to our results, it does not seem necessary to 
arrange frequent routine imaging follow-up studies in clini-
cally stable white European patients.
There are limited data comparing the imaging findings 
and clinically overt symptoms and signs. In a Japanese 
patient population with asymptomatic MMD 3/34 non-
surgically treated patients experienced silent radiologi-
cal changes, including cerebral infarction, CMB, and one 
progression of the disease stage on follow-up MRA in the 
43.7 months follow-up period [12]. In another Japanese 
study silent CMBs were found in 2 of 20 asymptomatic 
patients during the 48.8 months follow-up time [13]. The 
number of asymptomatic patients in our study was small 
(n = 5) and their radiological findings were few, one CMB 
and one ivy sign.
Ishikawa described occurrence of CMBs in MMD [14]. 
Incidence of CMBs is found to be high, especially in the 
hemorrhagic onset-type MMD, and meta-analysis indicated 
that they may be an important factor for hemorrhagic stroke 
risk [4]. CMBs can be detected using T2*-weighted imaging 
(T2*WI) and/or susceptibility-weighted imaging (SWI). In 
Asian populations CMBs have been reported in 28.2–51.9% 
of the patients [2–4]. In a German population based study 
CMBs were found in 12.9% of their patient population 
(n = 101) [6] which is close to our 6% result and it seems that 
the incidence of CMBs is lower in European populations. 
Another German population based study found no CMBs 
after STA-MCA bypass surgery during a mean follow-up 
of 38.2 months [15]. Unfortunately blood-sensitive MRI 
sequences have not been widely used in earlier MRI imag-
ing sessions and therefore long-time follow-up data are not 
extensively available on this aspect.
Reported frequency of progression from unilateral to 
bilateral varies from 12 to 39% over 1–15 years of follow-up 
periods [16–22]. In our patient population none of the uni-
lateral cases progressed to bilateral during a mean follow-up 
of 71 months which could mean that the unilateral disease 
remains mainly unilateral or the progression to bilateral dis-
ease is an extremely slow process in most cases.
Ivy sign refers to the appearance of the brain on post-
contrast T1-weighted images or FLAIR images where 
prominent leptomeningeal collaterals with slow blood flow 
and profuse contrast enhancement appear as if the brain is 
covered with ivy (Fig. 1) [23]. Oh et al. found ivy sign in 8 
out of 12 patients (67%) [5]. Seo et al. found ivy sign in all 
of their 83 patients’ population [18]. In our population, ivy 
sign was present in 22% of the patients. Mori et al. found 
that the degree of the ivy sign showed a significant positive 
relationship with the severity of the ischemic symptoms and 
concluded that the ivy sign indicates decreased cerebral vas-
cular reserve in MMD [24]. In a recent study by Kronenburg 
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et al. they found that ivy sign was not related to the presence 
or absence of collaterals on DSA, nor did it reflect absent 
cerebrovascular reactivity [25]. Our ivy-positive patients 
did not differ from our ivy sign-negative patients in terms 
of other imaging parameters or clinical characteristics. The 
pathophysiology of ivy sign and its clinical significance is so 
far unresolved. While interpretation of images on the pres-
ence and severity of ivy sign may differ between centers, it 
still seems that ivy sign is far less usual in white patients 
compared to Asian MMD patients.
MMD patients (n = 21) harbored more WMLs than con-
trols with the symptomatic side of the brain being more 
affected and suggested that WMLs might precede transient 
ischemic attacks (TIAs) [26]. Same study showed that WML 
volume decreased after revascularization surgery [26]. In our 
study, only 3 patients (9%) had WMLs and only one of them 
had had revascularization surgery. In the previous imaging 
only one had WMLs, but again unfortunately only 26/32 
of the patients had FLAIR-sequence done. In a Japanese 
population WMLs were present in 57/100 hemispheres [27]. 
Our patients were slightly older that the patients in these two 
studies, therefore, the differences in the presence and extent 
of WMLs are not explained by a younger population in our 
study. Again, it appears that the Finnish MMA patients have 
substantially less WML than Asian patients.
Our study has several limitations. Unfortunately we could 
not include all our HUH-MMA database patients because 
of long distances in our country and logistical difficulties 
of arranging radiological standardized follow-up leaving us 
with a smaller number of patients who lived nearby. The 
imaging time points were not standardized and included a 
range of 6–270 months from the previous last available MRI/
MRA or a range of 6–380 months from the initial MMA 
diagnosis. Because only the latter imaging was done with 
same sequences to all patients, comparing the findings of 
previous and latest images could not be done in all cases. 
The strength of our study is well investigated patients all 
of Finnish origin (Caucasian) and living in Finland with a 
homogenous patient population. Because there are only lim-
ited data on follow-up imaging changes in MMA, our study, 
adds new data to the field.
In conclusion, during a mean 64 month follow-up imag-
ing study, we detected fewer ivy sign, CMBs and WMLs 
than previously reported in MMD patients and detected only 
slight deteriorations which support our previous finding of 
relatively benign course of MMA in our Finnish patient 
population.
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